Evidence map›Paper›PMID 37631078›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Use of Nanocarriers Containing Antitrypanosomal Drugs for the Treatment of Chagas Disease.

Diogo de Freitas Paiva, Ana Paula Dos Santos Matos, Denise de Abreu Garófalo, Tatielle do Nascimento, Mariana Sato de Souza de Bustamante Monteiro, Ralph Santos-Oliveira, Eduardo Ricci-Junior

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Diogo de Freitas PaivaLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
Ana Paula Dos Santos MatosLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-2691-5335
Denise de Abreu GarófaloLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
Tatielle do NascimentoLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
Mariana Sato de Souza de Bustamante MonteiroLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
Ralph Santos-OliveiraNuclear Engineering Institute (IEN), University Campus of the Federal University of Rio de Janeiro, Rio de Janeiro 21941-906, Brazil.ORCID 0000-0002-0905-481X
Eduardo Ricci-JuniorLaboratory of Pharmaceutical Nanotechnology, Department of Drugs and Medications, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-2550-696X
Universidade Federal do Rio de Janeiro · BR

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.077/2021 (Cientista do Nosso Estado - FAPERJ)Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.136/2021 (Apoio aos Programas e Cursos de Pós-graduação Stricto Sensu do Estado do 661 Rio de Janeiro/ FAPER)National Council for Scientific and Technological Development 309522/2020-0 (Bolsa Produtividade em Pesquisa PQ2)
6 · The paper itself

Abstract

Chagas disease, caused by the

Indexed as

Chagas diseasein vivo assaysnanocarriersTrypanosoma cruzi

Identifiers

PMID37631078
PMCPMC10459817
OpenAlexW4385878294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.